Literature DB >> 11544414

Human liver allograft acceptance and the "tolerance assay": in vitro anti-donor T cell assays show hyporeactivity to donor cells, but unlike DTH, fail to detect linked suppression.

F Geissler1, E Jankowska-Gan, L D DeVito-Haynes, T Rhein, M Kalayoglu, H W Sollinger, W J Burlingham.   

Abstract

Human allograft acceptance is associated with immune regulation, characterized by donor-antigen-linked suppression of delayed-type hypersensitivity (DTH). We wished to determine if "classical" in vitro assays of alloreactivity could also detect linked suppression and thus be useful in the clinical diagnosis of active immune regulation. We analyzed peripheral blood mononuclear cells from a group of eight liver transplant recipients, one of whom had stopped all immunosuppression 4.5 years ago yet continues to have good graft function (graft acceptor). The regulator phenotype was defined as the ability to suppress a DTH response to a recall antigen in the presence of donor antigen. Using the trans vivo DTH test, we identified four regulators, and four nonregulators. When we tested two of the regulators for in vitro mixed lymphocyte culture (MLC) and cytotoxic T lymphocyte (CTL) responses to B-lymphoblastoid cell lines (B-LCL), we found both patients to be specifically hyporesponsive to donor compared with third-party B-LCL stimulators. However, in contrast to the linked suppression of DTH seen when a given B-LCL expressed donor-type HLA-B antigens, there was no evidence of linked suppression in vitro, either in CTL, proliferative, or interferon-gamma cytokine release assays. The primary CTL hyporesponsiveness to donor B-LCL could not be reversed by neutralizing antibodies to transforming growth factor beta or interleukin-10, which could restore a strong DTH response to donor B-LCL. We conclude that DTH analysis can readily detect donor antigen-linked suppression in liver transplant recipients. CTL and MLC tests failed to do so. These findings may be relevant to the development of a tolerance assay suitable for use in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11544414     DOI: 10.1097/00007890-200108270-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Successful reduction of immunosuppression in older renal transplant recipients who exhibit donor-specific regulation.

Authors:  Ewa Jankowska-Gan; Hans W Sollinger; John D Pirsch; Junchao Cai; Julio Pascual; Lynn D Haynes; Alenjandro Munoz del Rio; William J Burlingham
Journal:  Transplantation       Date:  2009-08-27       Impact factor: 4.939

2.  CpG oligodeoxynucleotide triggers the liver inflammatory reaction and abrogates spontaneous tolerance.

Authors:  Lian-Li Ma; Xiudan Gao; Liping Liu; Zhidan Xiang; Timothy S Blackwell; Philip Williams; Ravi S Chari; Deng-Ping Yin
Journal:  Liver Transpl       Date:  2009-08       Impact factor: 5.799

3.  Trans-vivo delayed type hypersensitivity assay for antigen specific regulation.

Authors:  Ewa Jankowska-Gan; Subramanya Hegde; William J Burlingham
Journal:  J Vis Exp       Date:  2013-05-02       Impact factor: 1.355

4.  Serial assessment of immune status by circulating CD8 effector T cell frequencies for posttransplant infectious complications.

Authors:  Shinji Uemoto; Kazue Ozawa; Hiroto Egawa; Yasutsugu Takada; Hiroshi Sato; Satoshi Teramukai; Mureo Kasahara; Kohei Ogawa; Masako Ono; Kenji Takai; Masanori Fukushima; Kayo Inaba; Koichi Tanaka
Journal:  Clin Dev Immunol       Date:  2008
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.